BR0014331A - Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença - Google Patents
Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doençaInfo
- Publication number
- BR0014331A BR0014331A BR0014331-6A BR0014331A BR0014331A BR 0014331 A BR0014331 A BR 0014331A BR 0014331 A BR0014331 A BR 0014331A BR 0014331 A BR0014331 A BR 0014331A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- chain
- synthesizing enzyme
- optionally substituted
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 title abstract 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 title abstract 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229940031439 squalene Drugs 0.000 title abstract 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 title abstract 3
- 230000002194 synthesizing effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940125532 enzyme inhibitor Drugs 0.000 title abstract 2
- 239000002532 enzyme inhibitor Substances 0.000 title abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- -1 QUINUCLIDINE COMPOUND Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO, INIBIDOR DE ENZIMA SINTETIZADORA DE ESQUALENO, COMPOSIçãO MEDICINAL, PROCESSO PARA A PRODUçãO DE UM COMPOSTO QUINUCLIDìNICO E PROCESSO PARA PREVENçãO OU CURA DE UMA DOENçA". A presente invenção proporciona um inibidor excelente para a enzima sintetizadora de esqualeno. Especificamente, ela apresenta um composto (I), representado por meio da fórmula que se segue, um de seus sais ou hidratos. Na qual R^ 1^ representa (1) um átomo de hidrogênio ou (2) um grupo hidroxila; HAr representa um heterociclo aromático que pode estar substituído com 1 a 3 grupos; Ar representa um anel aromático opcionalmente substituído; W significa uma cadeia representada por (1) -CH~ 2~CH~ 2~-, que pode estar substituída, (2) -CH=CH-, que pode estar substituída, (3) C<154>C-, (4) -NH-CO-, (5) -CO-NH-, (6) -NH-CH~ 2~-, (7) -CH~ 2~-NH-, (8) -CH~ 2~-CO-, (9) -CO-CH~ 2~-, (10) -NH-S(O)~ 1~-, (11) -S(O)~ 1~-NH-, (12) -CH~ 2~-S(O)~ 1~-, ou (13) -S(O)~ 1~-CH2-, (em que 1 representa 0, 1 ou 2); e X significa uma cadeia representada por meio de (1) uma ligação simples, (2) uma cadeia alquilênica C~ 1-6~, opcionalmente substituída, (3) uma cadeia alquenilênica C~ 2-6~, opcionalmente substituída, (4) uma cadeia alquinilênica C~ 2-6~,opcionalmente substuída, (5) uma fórmula -Q- (em que Q representa um átomo de oxigênio, um átomo de enxofre, CO ou N (R^ 2^ ) (em que R^ 2^ representa um grupo alquila C^ 1-6^ ou um grupo alcoxi C^ 1-6^, (6) -NH-CO-, (7) -CO-NH-, (8) -NH-CH^ 2^-, (9) -CH^ 2^-NH-, (10) -CH^ 2^-CO-, (11) -CO-CH~ 2~, (12) -NH-S(O)~ m~-, (13) -S(O)~ m~-NH-, (14) -CH~ 2~-S (O)~ m~-, (15) -S (O)~ m~-CH^ 2^-, (em que m representa 0, 1 ou 2) ou (16) - (CH~ 2~)~ n~-O- (em que n representa um inteiro de 1 a 6).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27390599 | 1999-09-28 | ||
| JP2000179352 | 2000-06-15 | ||
| PCT/JP2000/006665 WO2001023383A1 (en) | 1999-09-28 | 2000-09-27 | Quinuclidine compounds and drugs containing the same as the active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014331A true BR0014331A (pt) | 2003-06-10 |
Family
ID=26550809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014331-6A BR0014331A (pt) | 1999-09-28 | 2000-09-27 | Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6599917B1 (pt) |
| EP (1) | EP1217001B1 (pt) |
| JP (1) | JP4206212B2 (pt) |
| KR (1) | KR100694687B1 (pt) |
| CN (1) | CN100334085C (pt) |
| AT (1) | ATE312100T1 (pt) |
| AU (1) | AU782114B2 (pt) |
| BR (1) | BR0014331A (pt) |
| CA (1) | CA2385995C (pt) |
| DE (1) | DE60024651T2 (pt) |
| DK (1) | DK1217001T3 (pt) |
| ES (1) | ES2252063T3 (pt) |
| HU (1) | HUP0203514A3 (pt) |
| IL (2) | IL148631A0 (pt) |
| MX (1) | MXPA02003167A (pt) |
| NO (1) | NO328218B1 (pt) |
| NZ (1) | NZ517788A (pt) |
| RU (1) | RU2266905C2 (pt) |
| TW (1) | TWI282794B (pt) |
| WO (1) | WO2001023383A1 (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| US7112593B2 (en) | 2001-03-27 | 2006-09-26 | Eisai Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| EP1256573A1 (en) | 2001-05-09 | 2002-11-13 | Eisai Co., Ltd. | Process for producing stereoisomer of pyrrolidine derivative |
| RU2004110717A (ru) * | 2001-10-17 | 2005-10-20 | Юсиби, С.А. (Be) | Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов |
| US7361671B2 (en) * | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| DE10225537A1 (de) * | 2002-06-10 | 2003-12-18 | Bayer Ag | N-alkylierte Thiazoliumsalze und Verfahren zu deren Herstellung |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| US7432281B2 (en) * | 2003-10-07 | 2008-10-07 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| RU2417225C2 (ru) | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| CA2679198C (en) | 2007-02-26 | 2011-07-12 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CA2799926A1 (en) | 2010-05-28 | 2011-12-01 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| DK3738434T3 (da) | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| CN104884449A (zh) | 2012-10-31 | 2015-09-02 | 拜尔农作物科学股份公司 | 作为害虫防治剂的新的杂环化合物 |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T2 (sl) | 2014-02-07 | 2024-10-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| HRP20200638T1 (hr) | 2015-06-03 | 2020-07-10 | F. Hoffmann - La Roche Ag | Derivati etinila |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2105655A1 (en) * | 1991-03-08 | 1992-09-09 | Kent Neuenschwander | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
| US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| GB9127279D0 (en) | 1991-12-23 | 1992-02-19 | Ici Plc | Heterocyclic derivatives |
| JPH05310732A (ja) * | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| GB9207961D0 (en) | 1992-04-10 | 1992-05-27 | Ici Plc | Heterocyclic derivatives |
| GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| AU7394394A (en) | 1992-10-13 | 1995-12-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
| GB9226573D0 (en) * | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
| IL109451A0 (en) | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| GB9412145D0 (en) | 1994-06-17 | 1994-08-10 | Zeneca Ltd | Heterocycles |
| JPH08134067A (ja) | 1994-11-11 | 1996-05-28 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| JPH08269056A (ja) | 1995-03-29 | 1996-10-15 | Chugai Pharmaceut Co Ltd | スクアレンシンセターゼ阻害作用を有するキヌクリジン誘導体 |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| JP2000511532A (ja) | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
-
2000
- 2000-09-27 AT AT00962889T patent/ATE312100T1/de not_active IP Right Cessation
- 2000-09-27 DE DE60024651T patent/DE60024651T2/de not_active Expired - Lifetime
- 2000-09-27 ES ES00962889T patent/ES2252063T3/es not_active Expired - Lifetime
- 2000-09-27 HU HU0203514A patent/HUP0203514A3/hu unknown
- 2000-09-27 WO PCT/JP2000/006665 patent/WO2001023383A1/ja not_active Ceased
- 2000-09-27 MX MXPA02003167A patent/MXPA02003167A/es active IP Right Grant
- 2000-09-27 RU RU2002111344/04A patent/RU2266905C2/ru not_active IP Right Cessation
- 2000-09-27 EP EP00962889A patent/EP1217001B1/en not_active Expired - Lifetime
- 2000-09-27 IL IL14863100A patent/IL148631A0/xx unknown
- 2000-09-27 DK DK00962889T patent/DK1217001T3/da active
- 2000-09-27 CA CA002385995A patent/CA2385995C/en not_active Expired - Fee Related
- 2000-09-27 TW TW089119958A patent/TWI282794B/zh not_active IP Right Cessation
- 2000-09-27 BR BR0014331-6A patent/BR0014331A/pt not_active Application Discontinuation
- 2000-09-27 CN CNB00813541XA patent/CN100334085C/zh not_active Expired - Fee Related
- 2000-09-27 AU AU74464/00A patent/AU782114B2/en not_active Ceased
- 2000-09-27 US US10/088,554 patent/US6599917B1/en not_active Expired - Fee Related
- 2000-09-27 NZ NZ517788A patent/NZ517788A/en not_active IP Right Cessation
- 2000-09-27 JP JP2001526535A patent/JP4206212B2/ja not_active Expired - Fee Related
- 2000-09-27 KR KR1020027003952A patent/KR100694687B1/ko not_active Expired - Fee Related
-
2002
- 2002-03-12 IL IL148631A patent/IL148631A/en not_active IP Right Cessation
- 2002-03-26 NO NO20021528A patent/NO328218B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1217001A4 (en) | 2002-12-18 |
| HUP0203514A2 (hu) | 2003-03-28 |
| ES2252063T3 (es) | 2006-05-16 |
| NZ517788A (en) | 2003-11-28 |
| ATE312100T1 (de) | 2005-12-15 |
| EP1217001A1 (en) | 2002-06-26 |
| DE60024651T2 (de) | 2006-09-28 |
| CA2385995C (en) | 2009-06-16 |
| CA2385995A1 (en) | 2001-04-05 |
| AU7446400A (en) | 2001-04-30 |
| CN1377349A (zh) | 2002-10-30 |
| IL148631A0 (en) | 2002-09-12 |
| US6599917B1 (en) | 2003-07-29 |
| KR20020034197A (ko) | 2002-05-08 |
| JP4206212B2 (ja) | 2009-01-07 |
| DE60024651D1 (de) | 2006-01-12 |
| MXPA02003167A (es) | 2003-10-06 |
| AU782114B2 (en) | 2005-07-07 |
| HUP0203514A3 (en) | 2004-01-28 |
| NO20021528D0 (no) | 2002-03-26 |
| NO20021528L (no) | 2002-05-28 |
| DK1217001T3 (da) | 2006-03-20 |
| KR100694687B1 (ko) | 2007-03-13 |
| EP1217001B1 (en) | 2005-12-07 |
| IL148631A (en) | 2010-04-29 |
| NO328218B1 (no) | 2010-01-11 |
| WO2001023383A1 (en) | 2001-04-05 |
| CN100334085C (zh) | 2007-08-29 |
| TWI282794B (en) | 2007-06-21 |
| RU2266905C2 (ru) | 2005-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0114436A (pt) | Composto com anel de cinco elementos contendo nitrogênio alifático | |
| BRPI0417687A (pt) | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade | |
| BRPI0616393B8 (pt) | compostos heterocíclicos fundidos úteis como moduladores de quinase, composição farmacêutica e usos dos mesmos | |
| BR0316991A (pt) | Compostos de anel de 1,3-diidro-imidazol fundido | |
| BRPI0514644A (pt) | composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna | |
| BRPI0921701B8 (pt) | Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende | |
| ES2127722T3 (es) | Aralquilaminas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| BR9813835A (pt) | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica | |
| BR0212378A (pt) | Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio | |
| BR0213612A (pt) | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição | |
| BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
| BRPI0406721A (pt) | Compostos condensados de furano | |
| BRPI0511186A (pt) | composto, pró-droga do composto, composição farmacêutica, uso do composto, e, processo para preparar o composto | |
| BRPI0810524B8 (pt) | derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado | |
| BR0314133A (pt) | Métodos para a preparação, isolamento e purificação de epotilona b e raios x de estruturas de cristal de epotilona b | |
| ATE487162T1 (de) | Neue sulfoniumverbindung, diese enthaltende lichtempfindliche zusammensetzung und strukturbildungsverfahren unter verwendung der lichtempfindlichen zusammensetzung | |
| BRPI0408338A (pt) | piperidinas substituìdas como novos inibidores de mdm2-p53 | |
| BR0310032A (pt) | Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos | |
| UY25114A1 (es) | Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos. | |
| NO20062617L (no) | Anvendelse av glukosidase inhibitorer for terapi av mucovisidose | |
| AR025103A1 (es) | Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos | |
| BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
| BR0311410A (pt) | Composto de piperidina | |
| BR0310033A (pt) | Inibidores da transcriptase reversa de não-nucleosìdeo | |
| BR9911250A (pt) | Processo para preparação de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: EISAI R AND D MANAGEMENT CO., LTD. (JP) Free format text: TRANSFERIDO DE: EISAI CO., LTD. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07D 453/02; A61K 31/4545; A61K 31/444; A61K 31/506; A61K 31/439; A61P 43/00; A61P 3/06; A61P 9/10; C07M 7/00. Ipc: C07D 453/02 (2006.01) Ipc: C07D 453/02 (2006.01) |